Koers Maricann Group Inc Deutsche Boerse AG
Aandelen
CA5667241007
Farmaceutische producten
Omzet 2016 | 4,06 3,74 | Omzet 2017 | 3,22 2,97 | Marktkapitalisatie | 203 mln. 187 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -8 mln. -7,37 mln. | Nettowinst (verlies) 2017 | -67 mln. -61,76 mln. | EV/omzet 2016 * | - |
Nettoschuld 2016 | 9,13 8,41 | Nettoliquiditeiten 2017 | 0,42 0,39 | EV/omzet 2017 | 63.046.727 x |
K/w-verhouding 2016 * |
-
| K/w-verhouding 2017 |
-2,13
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+42,07% | 6,28 mld. | |
-21,20% | 4,25 mld. | |
+5,38% | 3,36 mld. | |
-16,98% | 2,96 mld. | |
-5,82% | 2,45 mld. | |
+45,47% | 1,97 mld. | |
-12,67% | 1,61 mld. | |
-3,91% | 1,6 mld. | |
+44,56% | 1,51 mld. |